Protalix Biotherapeutics Inc

PLX

$1.10

Closing

▲0.92%

1D

▼-38.20%

YTD

PLX

BBG001SBVMW4

Market cap

$80.65M

52 week high

$2.07

52 week low

$1.02

Volume

6,682

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$80.65M

Analysts' Rating

BUY

Price Target (Mean)

12.00

Total Analysts

0

P/E

18.13

Operating Margin

-129.56%

Beta

0.78

Revenue Growth (Annual)

-60.91%

52 week high

$2.07

52 week low

$1.02

Div. Yield

%

EPS Annual Growth

-14.29

Company Profile

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.